Rep. Lloyd Doggett Buys Shares of Johnson & Johnson (NYSE:JNJ)

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on October 5th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on September 8th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/17/2026.
• Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 9/11/2026.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 9/10/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/17/2026.

Johnson & Johnson Trading Up 0.8%

Johnson & Johnson stock opened at $254.85 on Wednesday. Johnson & Johnson has a 1 year low of $182.94 and a 1 year high of $281.07. The firm’s 50 day moving average price is $265.86 and its 200-day moving average price is $248.63. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock has a market cap of $614.17 billion, a P/E ratio of 29.53, a PEG ratio of 2.48 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the previous year, the firm posted $2.77 EPS. Johnson & Johnson’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.54 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. HSBC lifted their target price on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. The Goldman Sachs Group restated a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research note on Monday, August 3rd. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $276.22.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: RBC Capital Markets said acceleration in J&J’s Innovative Medicine business is helping offset continuing MedTech headwinds. The company’s diversified portfolio and new drug launches remain important supports for earnings growth. Johnson & Johnson’s Innovative Medicines Momentum Offsets MedTech Headwinds
• Positive Sentiment: Analysts see potential for a MedTech recovery in the second half, particularly from Vision, Orthopedics and Surgery. That could help counter pressure from Abiomed and broader competition. Can J&J’s MedTech Business Rebound in Q3 After Q2 Slowdown?
• Positive Sentiment: J&J continues to attract defensive-income investors because healthcare demand is relatively resilient during downturns. Its dividend history and diversified operations may provide support if economic growth slows. Looking for a Dividend Stock That Can Weather a Downturn?
• Neutral Sentiment: CEO Joaquin Duato said artificial intelligence should be embraced as a force multiplier. The comments reinforce J&J’s technology strategy but did not include a specific financial target or near-term catalyst. Johnson & Johnson CEO Says AI Has to Be Embraced
• Negative Sentiment: Investors remain concerned that the upcoming patent cliff could pressure growth after 2026. The key issue for the October 13 report is likely management’s outlook for replacement products, rather than quarterly EPS alone. The Next Patent Cliff Will Test J&J’s Replacement Engine
• Negative Sentiment: Zacks’ pre-earnings analysis suggests J&J may not have the strongest combination of earnings-estimate revisions and surprise indicators for an imminent earnings beat, increasing event risk ahead of results. Johnson & Johnson Earnings Expected to Grow

Insider Activity at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP boosted its stake in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares during the period. Deutsche Bank AG increased its stake in Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Johnson & Johnson by 8.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock valued at $3,575,255,000 after buying an additional 1,376,828 shares in the last quarter. Amundi boosted its position in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares during the period. Finally, Nuveen LLC grew its stake in Johnson & Johnson by 6.9% in the 4th quarter. Nuveen LLC now owns 10,609,171 shares of the company’s stock worth $2,195,568,000 after acquiring an additional 683,967 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.